Aim of the study: To evaluate the efficacy of a nutraceutical compound containing Uticlin® (D-mannose, cranberry, bearberry, Olea europaea), inulin, Orthosiphon and Lactobacillus acidophilus, in preventing recurrent urinary tract infections (UTIs) in menopausal women. Material and methods: This was a prospective cohort study of menopausal women recruited with a history of recurrent UTIs in the previous twelve months and who intended to treat their bladder problem without the use of antibiotics and/or anti-inflammatories. Women were proposed the use of an oral nutraceutical compound. The drug was taken for ten days, every month. Women were assigned to two parallel cohorts: patients using (group 1) or not using (group 2) this nutraceutical compound. The primary objective of the study was to evaluate the number of women with less than two infective episodes in the 6-month follow-up and less than three episodes in the 12-month follow-up. The secondary endpoints were to evaluate the reduction of related symptoms at 12-month follow-up, according to the Visual Analog Scale (VAS). Results: At 6 months of therapy, the reduction in the number of patients with ≥ 2 UTIs was statistically significant (p < 0.05) compared to baseline only in group 1. At 12 months, the number of patients who were disease-free was significantly higher (p < 0.05) in group 1 compared to group 2. Moreover, the improvement of related symptoms was statistically significant (p < 0.05) in group 1, as shown by the reduction in the VAS scale value. Conclusions: In menopausal women, the combination of D-mannose, inulin, cranberry, bearberry, Olea europaea, Orthosiphon and Lactobacillus acidophilus SGL 11 per os represents a useful therapy for recurrent UTIs in women wanting a natural approach.
Materials and MethodsAfter obtaining their informed consent, the authors selected 42 patients whose histodiagnosis had revealed pelvic endometriosis and gathered them at the general practice for gynaecology and obstetrics and/or sterility of the
This study was designed to measure the beneficial effects of a combination of nutraceutics containing soy isoflavones (80 mg) and to evaluate the effect of soy isoflavones on hot flushes (HF) and quality of life in a clinical setting, as the authors conducted an observational study. Materials and Methods: This study was conducted on 92 patients with complaints of hot flashes, divided into two groups of 46 each. Group 1 received no therapy and group 2 received 80 mg of isoflavones daily for six months. The patients were interviewed to calculate hot flashes, global and depression scores and were rescored after 2, 4, 8, 12 and 24 weeks. The primary outcome measure was a change in the HF score from baseline. Results: A total of 92 patients, 46 (50%) in the treated group and 46 (50%) in the untreated group, entered the study. Extracts containing high levels of genistein (a substance derived from soy) appeared to reduce the number of daily HF and need to be investigated further. No indication suggested that discrepant results were due to the amount of isoflavones in the active treatment arm, the severity of vasomotor symptoms or trial quality factors. Also, no evidence indicated that these treatments caused oestrogenic stimulation of the endometrium or of the vagina or other adverse effects when used for up to one year. Conclusions: This observational trial suggests a possible beneficial effect of a dietary soy supplement containing 80 mg of isoflavones/day in the management of menopausal symptoms such as HF.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.